Market Overview

UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Related MYGN
Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes
Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.

Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."

Myriad Genetics closed yesterday at $25.75.

Latest Ratings for MYGN

Sep 2015Stephens & Co.MaintainsOverweight
Sep 2015JefferiesMaintainsHold
Sep 2015Piper JaffrayMaintainsOverweight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings


Related Articles (MYGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters